Prospective Trial Data on MRD Testing in Early-Stage CRC

A retrospective analysis shows that trifluridine/tipiracil with or without bevacizumab given biweekly was favorable in those with colorectal cancer.

The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

Counseling received prior to colorectal surgery using 3-dimensional–printed anatomic models reduced mean anxiety scores vs conventional counseling.

Oncology pharmacist Jagoda Misniakiewicz, PharmD, discusses the potential efficacy and safety profile of fruquintinib in patients with metastatic CRC.

Emergent alteration patterns were similarly diverse across treatment arms in the phase 3 CodeBreaK 300 study.

The median PFS was 54.1 months with nivolumab/ipilimumab vs 5.9 months with chemotherapy in patients with MSI-H/dMMR CRC.